Literature DB >> 19424005

The immunosuppressive properties of mesenchymal stem cells.

Georg Siegel1, Richard Schäfer, Francesco Dazzi.   

Abstract

Mesenchymal stem cells (MSC) are a type of multipotent progenitor cell, originally isolated from the bone marrow. In addition to multilineage differentiation and participation in the hematopoietic niche, they exert powerful immunomodulatory effects, which include inhibition of proliferation and function of T cells, B cells, and natural killer cells. These unique properties make MSC of great interest for clinical applications in tissue engineering and immunosuppression. Underlying the MSC-mediated immunomodulatory mechanisms is a nonspecific antiproliferative effect, which is the consequence of cyclin D2 inhibition. Of special interest are the molecular mechanisms, by which MSC influence their target cells. Several studies have been conducted in this field, and the current data suggest roles for indoleamine 2,3-dioxygenase, prostaglandin E2, nitric oxide, histocompatibility locus antigen-G, insulin-like growth factor-binding proteins, and tolerogenic antigen-presenting cells. Understanding these mechanisms is crucial for future use of MSC in research and clinical applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424005     DOI: 10.1097/TP.0b013e3181a285b0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  76 in total

Review 1.  Mesenchymal stem cell mechanobiology.

Authors:  Alesha B Castillo; Christopher R Jacobs
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

2.  Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.

Authors:  L Zazzeroni; G Lanzoni; G Pasquinelli; C Ricordi
Journal:  CellR4 Repair Replace Regen Reprogram       Date:  2017-09-29

Review 3.  Angiogenesis, neurogenesis and brain recovery of function following injury.

Authors:  Ye Xiong; Asim Mahmood; Michael Chopp
Journal:  Curr Opin Investig Drugs       Date:  2010-03

4.  Schwann cell coculture improves the therapeutic effect of bone marrow stromal cells on recovery in spinal cord-injured mice.

Authors:  Xiaoyun Xu; Nicole Geremia; Feng Bao; Anna Pniak; Melissa Rossoni; Arthur Brown
Journal:  Cell Transplant       Date:  2010-11-19       Impact factor: 4.064

5.  Mesenchymal stem cells: new aspect in cell-based regenerative therapy.

Authors:  Mozhdeh Mohammadian; Karim Shamsasenjan; Parisa Lotfi Nezhad; Mehdi Talebi; Mehdi Jahedi; Hossein Nickkhah; Neda Minayi; Aliakbar Movassagh Pour
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 6.  Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation.

Authors:  Charalampos Pontikoglou; Frédéric Deschaseaux; Luc Sensebé; Helen A Papadaki
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

Review 7.  [Cutaneous mesenchymal stem cells. Current status of research and potential clinical applications].

Authors:  K Sellheyer; D Krahl
Journal:  Hautarzt       Date:  2010-05       Impact factor: 0.751

8.  Expression of blood group genes by mesenchymal stem cells.

Authors:  Richard Schäfer; Martina Schnaidt; Roland A Klaffschenkel; Georg Siegel; Michael Schüle; Maria Anna Rädlein; Ursula Hermanutz-Klein; Miriam Ayturan; Marine Buadze; Christoph Gassner; Lusine Danielyan; Torsten Kluba; Hinnak Northoff; Willy A Flegel
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

9.  Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells.

Authors:  J Niu; W Yue; Y Song; Y Zhang; X Qi; Z Wang; B Liu; H Shen; X Hu
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

10.  The immunomodulatory properties of human bone marrow-derived mesenchymal stromal cells are defined according to multiple immunobiological criteria.

Authors:  Hussein Fayyad-Kazan; Wissam H Faour; Bassam Badran; Laurence Lagneaux; Mehdi Najar
Journal:  Inflamm Res       Date:  2016-03-08       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.